Global Age Related Macular Degeneration Amd Disease Anti Vegf Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2022 –2029 |
 시장 규모(기준 연도) |
USD 13,677.02 Million |
 시장 규모(예측 연도) |
USD 22,951.90 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
>전 세계 연령 관련 황반변성(AMD) 질환 - 항 VEGF 시장, 유형(건성 AMD 및 습성 AMD), 최종 사용자(병원, 전문 클리닉, 외래 수술 센터 , 가정 의료 및 기타), 유통 채널(직접 입찰 및 소매 판매)별 - 업계 동향 및 2031년까지의 예측.
연령 관련 황반변성(AMD) 질환 - 항 VEGF 시장 분석 및 통찰력
연령 관련 황반변성(AMD)은 시간이 지남에 따라 악화될 수 있는 안구 질환입니다. 60세 이상의 사람들에게 심각하고 영구적인 시력 상실의 주요 원인입니다. 노화는 전 세계적으로 초기 AMD가 발생하는 위험 요인 중 하나입니다. 전 세계 노인 인구가 급속도로 증가하고 있습니다. 연령이 증가함에 따라 만성 질환 유병률이 증가함에 따라 노인 환자도 함께 증가합니다. 질병 진단은 다양한 단계에서 가능하며, 유전자 검사 와 망막 영상은 질병을 감지하는 기술 중 일부입니다. 질병 진단은 주로 광학 영상 기술과 기타 표준 프로세스를 통해 수행됩니다.
치료법은 없지만 연령 관련 황반변성(AMD)에 대한 치료는 질병을 늦추고 심각한 시력 상실을 예방할 수 있습니다. 연령 관련 황반변성(AMD) 질병 치료에는 일반적으로 약물과 진단 제품이 포함됩니다. 이러한 기술은 망막의 손상된 부분에 도달하고 치료법으로 치료하기 쉽게 하는 데 사용됩니다.
글로벌 연령 관련 황반변성(AMD) 질환 - 항 VEGF 시장은 2024년에서 2031년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2024년에서 2031년의 예측 기간 동안 6.8%의 CAGR로 성장하고 있으며 2023년의 13,677.02백만 달러에서 2031년까지 22,951.90백만 달러에 도달할 것으로 예상된다고 분석합니다.
글로벌 연령 관련 황반변성(AMD) 질환 - 항 VEGF 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 당사에 문의하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다. 다양한 지역의 개발도상국에 있는 소매점의 확장성과 사업 확장, 기계 및 약물 제품의 안전한 유통을 위한 공급업체와의 파트너십은 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2024년부터 2031년까지 |
|
기준 연도 |
2023 |
|
역사적 연도 |
2022 (2016-2021년까지 사용자 정의 가능) |
|
양적 단위 |
수익 (단위: USD 백만) |
|
다루는 세그먼트 |
유형(건성 AMD 및 습성 AMD), 최종 사용자(병원, 전문 클리닉, 외래 수술 센터, 홈 헬스케어 및 기타), 유통 채널(직접 입찰 및 소매 판매) |
|
적용 국가 |
미국, 캐나다, 멕시코, 독일, 프랑스, 이탈리아, 영국, 스페인, 러시아, 오스트리아, 네덜란드, 헝가리, 폴란드, 스위스, 터키, 노르웨이, 리투아니아, 아일랜드, 유럽의 나머지 지역, 일본, 중국, 인도, 호주, 싱가포르, 한국, 말레이시아, 태국, 인도네시아, 필리핀, 베트남, 아시아 태평양의 나머지 지역, 브라질, 아르헨티나, 페루, 남미의 나머지 지역, 남아프리카, 이집트, 사우디 아라비아, 이스라엘, UAE, 쿠웨이트, 중동 및 아프리카의 나머지 지역 |
|
시장 참여자 포함 |
Regeneron Pharmaceuticals Inc., Biogen, Outlook Therapeutics, Inc., Sulentis, SA, Novartis AG, Genentech, Inc., Bayer AG, Adverum Biotechnologies, Inc., Gensight Biologics, REGENXBIO INC., OCUGEN, INC., MeiraGTX, Limited, Johnson & Johnson Services, Inc., IVERIC bio, Inc., An Astellas Company, KODIAK SCIENCES INC., 및 lonis Pharmaceuticals 등이 있습니다. |
시장 정의
항-VEGF 요법은 연령 관련 황반변성(AMD)과 같은 질환의 특징인 망막의 비정상적인 혈관 성장을 중단합니다. 이 약물은 VEGF의 작용을 억제하여 혈관 누출과 중앙 시력 영역(황반) 손상을 예방합니다. 눈 주사를 통해 투여하면 시력 상실을 늦추고 어떤 경우에는 시력을 개선합니다. AMD 관리에 중요한 이 표적 치료는 눈의 문제가 있는 혈관의 성장을 방해하여 질병의 진행을 억제합니다.
글로벌 연령 관련 황반변성(AMD) 질환 - 항VEGF 시장 역학
이 섹션에서는 시장 동인, 이점, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.
운전자
- 연령 관련 황반변성증의 유병률 증가
녹내장 , 백내장, 연령 관련 황반변성과 같은 시력을 위협하는 질병의 유병률은 인구 고령화와 기대 수명 증가로 인해 선진국에서 증가할 것으로 예상됩니다. 이들은 서구 취업 연령 인구에서 실명의 주요 원인으로 두드러집니다. 환자의 약 60%가 출생 직후 질병이 발생하는 심각한 시각 장애를 앓고 있는 것으로 추정되며, 이것이 시장 성장을 주도하고 있습니다.
- 주요 참여자의 전략적 이니셔티브 증가
협회는 주요 사업자가 기술을 한 사업자에게서 다른 사업자에게 전수하는 것과 함께 전 세계 다른 지역으로 사업을 확장하고, 제품 승인과 기관 연구를 확대하기 위해 이 거래를 활용합니다.
시장 참여자들은 파트너십, 제품 승인, 협업 등을 포함한 다양한 전략적 이니셔티브를 수행합니다. 이러한 이니셔티브는 시장에서의 입지를 강화하고 시장 확장을 촉진하는 데 도움이 됩니다. 게다가 일부 전략적 이니셔티브는 여러 고객 사이에서 제품에 대한 수요를 증가시켰습니다. 협업, 계약, 판매 계약 체결과 같은 전략적 이니셔티브가 시장을 주도할 것으로 예상됩니다.
기회
- 연구 개발 증가
연구 개발은 다양한 종류의 환자를 치료하기 위해 치료법을 수정하는 데 필수적입니다. 연령 관련 황반변성(AMD) 치료 및 시술에 대한 수요는 모든 국가에서 증가하고 있습니다. 이것이 회사가 환자와 의료 종사자에게 효과적인 치료를 성공적으로 제공하기 위해 연구 개발에 지속적으로 집중하는 이유입니다.
질병이 진행되고, 시력이 점점 손상되고, 망막 조직이 퇴화하고, 영구적인 손상이 발생하는 등 효과적인 증강 요인을 포함하여 특정 방식으로 개인에게만 효과가 나타날 수 있습니다.
도전/ 제약
- 치료 및 시술 비용이 높음
제품의 비용은 시장에서 중요한 요소입니다. 연령 관련 황반변성(AMD) 질환의 경우 일반적으로 매우 정교하고 정밀해야 하며 다른 사양은 제품 비용을 증가시킵니다. 게다가 장기간 치료와 관련된 비용은 평균 소득자가 감당하기 매우 어렵습니다. 중환자 치료 및 집중 치료실 서비스 이용은 전 세계적으로 증가하고 있으며, 비용이 많이 들기 때문에 현재 의료 시스템에서 주요 관심사입니다.
퇴행성 질환이 있는 환자는 일반적으로 빈번한 화폐화 및 기타 사용과 함께 장기간 치료를 받아야 하며, 이는 상당한 양의 의료 자원을 소모하게 됩니다. 장기적인 경제적 비용을 감당할 수 없는 대부분의 환자는 치료 초기 단계에서 퇴원합니다. 그러나 이는 진단 시 새로운 합병증의 가능성과 취약성을 증가시켜 추가적인 의료 자원과 치료를 요구하며, 이는 시장 성장을 재교육하고 있습니다.
- 치료에 대한 제한된 접근
질병의 치료는 해당 질병에 이용 가능한 서비스에 대한 접근성에 직접적으로 달려 있습니다. 다양한 유형의 연령 관련 황반변성(AMD) 질병의 치료율은 낮은 소득과 제한된 자원 등으로 인해 병원과 전문 병원에 대한 접근성이 제한되어 떨어집니다.
2019년 보고서에 실린 약물 부문의 주요 시장 참여자들과의 인터뷰에서 그들은 저개발 국가에서 진단 제품에 대한 접근성을 제공하는 데 어려움을 겪고 있다고 말했습니다. 전 세계적으로 약 2억 8,500만 명의 사람들이 시각 장애인이며, 이들 중 80%는 치료 가능한 안구 질환을 앓고 있지만, 적절한 치료, 제품 또는 사용 가능한 기술에 대한 접근성이 제한적이거나 전혀 없기 때문에 실명의 유병률이 증가하고 시장 성장이 감소합니다.
최근 개발 사항
- 2023년 11월, Regeneron Pharmaceuticals, Inc.는 샌프란시스코에서 열린 American Academy of Ophthalmology(AAO) 연례 회의에서 EYLEA HD(aflibercept) 주사액 8mg에 대한 장기적 결과와 주요 임상 데이터에 대한 새로운 분석을 발표했습니다. 이는 회사가 투자자를 유치하기 위해 노력하는 투자자 행사로, 이를 통해 회사가 R&D를 늘리는 데 도움이 됩니다.
- 2023년 8월, Astellas Pharma Inc.는 IZERVAY(avacincaptad pegol intravitreal solution)가 연령 관련 황반변성(AMD)으로 인한 지리적 위축(GA)을 치료하기 위해 미국 식품의약국(FDA)의 승인을 받을 것이라고 발표했습니다. 12개월 1차 종료점에서 GA 진행률은 새로운 보체 C5 억제제 IZERVAY를 사용한 두 가지 3상 임상 시험에서 통계적으로 유의미하게(p<0.01) 더 낮았으며, 이는 GA에 대한 유일한 승인된 치료법이 되었습니다.
- 2022년 11월, SA의 Sylentis는 신생혈관성 연령 관련 황반변성(AMD) 환자를 치료하기 위한 화합물 SYL1801을 사용한 새로운 2상 용량 탐색 시험에서 첫 번째 환자를 모집했다고 발표했습니다. 이는 무작위 이중 맹검 2상 시험으로, 각 피험자 그룹에 다른 용량 수준을 투여하는 3개의 평행 그룹이 있습니다. 이 연구는 이미 시작되었으며 여러 유럽 국가의 다양한 센터에서 90명의 환자를 모집할 예정입니다. 이 시험의 주요 목적은 신생혈관성 AMD 환자에게 6주 동안 매일 한 방울씩 투여하는 3가지 용량 모두에서 SYL1801의 시력에 미치는 효과를 평가하는 것입니다.
- 2022년 5월, Adverum Biotechnologies, Inc.는 회사가 2상 개발 계획을 뒷받침하는 ADVM-022의 효능 및 안전성 결과에 대한 데이터를 American Society of Gene and Cell Therapy(ASGCT) 2022 연례 회의에서 발표했다고 발표했습니다. 이는 후속 임상 시험에서 새로운 향상된 예방 스테로이드 요법으로 ADVM-022 용량을 평가하는 결과를 가져옵니다.
- 2022년 3월, Novartis AG는 Beovu(brolucizumab) 6mg가 당뇨병성 황반부 에도마(DME)로 인한 시각 장애를 치료하기 위해 유럽 위원회(EC)에서 승인되었다고 발표했습니다. Beovu는 2020년에 EC에서 습성 연령 관련 황반변성을 치료하기 위해 처음 승인되었습니다. DME 적응증은 이 약물의 두 번째 승인입니다. 유럽 공동체(EC)의 판결은 모든 27개 EU 회원국과 리히텐슈타인, 아이슬란드, 노르웨이에 적용됩니다.
글로벌 연령 관련 황반변성(AMD) 질환 - 항 VEGF 시장 범위
글로벌 연령 관련 황반변성(AMD) 질환 - 항 VEGF 시장은 유형, 최종 사용자, 유통 채널을 기준으로 세 가지 주요 세그먼트로 분류됩니다. 세그먼트 간 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
유형
- 건성 AMD
- 습성 AMD
시장은 유형을 기준으로 건성 AMD와 습성 AMD로 구분됩니다.
최종 사용자
- 병원
- 전문 클리닉
- 외래 수술 센터
- 홈 헬스케어
- 기타
최종 사용자를 기준으로 시장은 병원, 전문 병원, 외래 수술 센터, 가정 의료 서비스 및 기타로 구분됩니다.
유통 채널
- 소매 판매
- 직접 입찰
유통 채널을 기준으로 시장은 직접 입찰과 소매 판매로 구분됩니다.
지역 분석/통찰력: 글로벌 연령 관련 황반변성(AMD) 질환 - 항 VEGF 시장
전 세계 연령관련 황반변성(AMD) 질환 - 항 VEGF 시장은 유형, 최종 사용자, 유통 채널을 기준으로 세 가지 주요 부문으로 분류됩니다.
이 시장 보고서에 포함된 국가로는 미국, 캐나다, 멕시코, 독일, 프랑스, 이탈리아, 영국, 스페인, 러시아, 오스트리아, 네덜란드, 헝가리, 폴란드, 스위스, 터키, 노르웨이, 리투아니아, 아일랜드, 유럽의 기타 지역, 일본, 중국, 인도, 호주, 싱가포르, 한국, 말레이시아, 태국, 인도네시아, 필리핀, 베트남, 아시아 태평양의 기타 지역, 브라질, 아르헨티나, 페루, 남미의 기타 지역, 남아프리카 공화국, 이집트, 사우디 아라비아, 이스라엘, UAE, 쿠웨이트, 그리고 중동 및 아프리카의 기타 지역이 있습니다.
북미는 연령 관련 황반변성(AMD) 질환 - 항 VEGF의 유병률 증가로 인해 글로벌 연령 관련 황반변성(AMD) 질환을 지배할 것으로 예상됩니다. 미국은 전 세계적으로 가장 큰 R&D 지출을 하고 여러 국가와 무역 협정을 맺고 있어 북미 지역을 지배할 것으로 예상되며, 이는 소비자 진단 및 치료 제품에 대한 가장 큰 시장이 되기 때문입니다. 중국은 연령 관련 황반변성(AMD) 질환 - 항 VEGF 기반 제품의 대량 생산과 신흥 시장 및 확장으로 인한 수요 증가로 인해 아시아 태평양 지역을 지배할 것으로 예상됩니다. 독일은 치료에 대한 새로운 보상 정책을 가지고 있어 유럽 지역을 지배할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 점유율 분석: 글로벌 연령 관련 황반변성(AMD) 질환 - 항 VEGF 시장
글로벌 연령 관련 황반변성(AMD) 질환 - 항 VEGF 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭 및 호흡, 응용 프로그램 우세, 제품 유형 수명선 곡선이 있습니다. 제공된 위의 데이터 포인트는 회사의 시장 집중과만 관련이 있습니다.
글로벌 연령관련 황반변성(AMD) 질환 - 항 VEGF 시장에서 활동하는 주요 기업으로는 Regeneron Pharmaceuticals Inc., Biogen, Outlook Therapeutics, Inc., Sylentis, SA, Novartis AG, Genentech, Inc., Bayer AG, Adverum Biotechnologies, Inc., Gensight Biologics, REGENXBIO INC., OCUGEN, INC., MeiraGTx Limited, Johnson & Johnson Services, Inc., IVERIC bio, Inc., An Astellas Company, KODIAK SCIENCES INC., Ionis Pharmaceuticals 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTERS_
4.3 PRICING ANALYSIS
4.4 STRATEGIC INITIATIVES
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION
6.1.2 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS
6.1.3 INCREASE IN PIPELINE PRODUCTS
6.1.4 INCREASING GERIATRIC POPULATION
6.1.5 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD)
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 INCREASING RESEARCH AND DEVELOPMENT
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
6.4 CHALLENGES
6.4.1 LIMITED ACCESS TO TREATMENT
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS
7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE
7.1 OVERVIEW
7.2 WET AMD
7.2.1 MEDICATIONS
7.2.1.1 ANTI-VEGF THERAPY
7.2.1.2 OTHERS
7.2.2 SURGERY
7.3 DRY AMD
8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 SPECIALTY CLINICS
8.4 AMBULATORY SURGICAL CENTERS
8.5 HOME HEALTHCARE
8.6 OTHERS
9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 RETAIL SALES
9.2.1 HOSPITAL PHARMACIES
9.2.2 RETAIL PHARMACIES
9.2.3 OTHERS
9.3 DIRECT TENDER
10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 CANADA
10.2.3 MEXICO
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 U.K.
10.3.4 RUSSIA
10.3.5 ITALY
10.3.6 SPAIN
10.3.7 NETHERLANDS
10.3.8 SWITZERLAND
10.3.9 POLAND
10.3.10 TURKEY
10.3.11 AUSTRIA
10.3.12 HUNGARY
10.3.13 NORWAY
10.3.14 IRELAND
10.3.15 LITHUANIA
10.3.16 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 SINGAPORE
10.4.7 THAILAND
10.4.8 INDONESIA
10.4.9 PHILIPPINES
10.4.10 MALAYSIA
10.4.11 VIETNAM
10.4.12 REST OF ASIA-PACIFIC
10.5 SOUTH AMERICA
10.5.1 BRAZIL
10.5.2 ARGENTINA
10.5.3 PERU
10.5.4 REST OF SOUTH AMERICA
10.6 MIDDLE EAST AND AFRICA
10.6.1 SOUTH AFRICA
10.6.2 SAUDI ARABIA
10.6.3 U.A.E.
10.6.4 ISRAEL
10.6.5 EGYPT
10.6.6 KUWAIT
10.6.7 REST OF SOUTH AFRICA
11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: GLOBAL
12 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 REGENERON PHARMACEUTICALS INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 BAYER AG
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 GENENTECH, INC. (A SUBSIDIARY OF F.HOFFMANN- LA ROCHE LTD)
16.3.1 COMPANY SNAPSHOT
16.3.2 COMPANY SHARE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENT
16.4 NOVARTIS AG
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.4.5.1 AGREEMENT
16.5 IVERIC BIO (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ADVERUM BIOTECHNOLOGIES, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BIOGEN
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 GENSIGHT BIOLOGICS
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 IONIS PHARMACEUTICALS
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 JOHNSON &JOHNSON SERVICES, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 KODIAK SCIENCES INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 MEIRAGTX LIMITED
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
16.13 OCUGEN, INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 OUTLOOK THERAPEUTICS, INC.
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 REGENXBIO INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 SYLENTIS, S.A.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
표 목록
TABLE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 2 GLOBAL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 3 GLOBAL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 GLOBAL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 GLOBAL DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 7 GLOBAL HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 GLOBAL SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 GLOBAL AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 GLOBAL HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 GLOBAL OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 13 GLOBAL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 GLOBAL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 15 GLOBAL DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 24 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 25 U.S. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 U.S. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 28 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 29 U.S. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 30 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 31 CANADA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 32 CANADA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 34 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 35 CANADA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 36 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 MEXICO WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 38 MEXICO MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 39 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 40 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 41 MEXICO RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 43 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 46 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 47 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 48 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 49 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 50 GERMANY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 51 GERMANY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 53 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 54 GERMANY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 55 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 FRANCE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 FRANCE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 59 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 60 FRANCE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 61 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 U.K. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 U.K. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 64 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 65 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 66 U.K. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 67 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 RUSSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 RUSSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 71 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 72 RUSSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 73 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 ITALY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 ITALY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 77 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 78 ITALY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 79 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 SPAIN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 SPAIN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 83 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 84 SPAIN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 85 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 NETHERLANDS WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 NETHERLANDS MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 89 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 90 NETHERLANDS RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 91 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 SWITZERLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 SWITZERLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 94 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 95 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 96 SWITZERLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 97 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 POLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 POLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 101 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 102 POLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 103 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 TURKEY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 TURKEY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 107 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 108 TURKEY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 109 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 AUSTRIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 111 AUSTRIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 112 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 113 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 114 AUSTRIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 115 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 HUNGARY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 117 HUNGARY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 118 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 119 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 120 HUNGARY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 121 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 122 NORWAY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 123 NORWAY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 125 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 126 NORWAY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 127 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 IRELAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 IRELAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 131 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 132 IRELAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 133 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 LITHUANIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 135 LITHUANIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 136 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 137 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 138 LITHUANIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 139 REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 140 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 141 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 142 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 ASIA-PACIFIC MEDICATION IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 145 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 146 ASIA-PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 147 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 CHINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 CHINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 150 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 151 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 152 CHINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 JAPAN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 JAPAN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 157 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 158 JAPAN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 159 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 160 INDIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 INDIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 163 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 164 INDIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 165 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 SOUTH KOREA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 167 SOUTH KOREA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 168 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 169 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 170 SOUTH KOREA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 171 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 AUSTRALIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 AUSTRALIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 175 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 176 AUSTRALIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 177 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 SINGAPORE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 SINGAPORE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 181 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 182 SINGAPORE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 183 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 184 THAILAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 185 THAILAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 187 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 188 THAILAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 189 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 INDONESIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 INDONESIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 192 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 193 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 194 INDONESIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 195 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 196 PHILIPPINES WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 197 PHILIPPINES MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 199 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 200 PHILIPPINES RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 201 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 202 MALAYSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 MALAYSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 205 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 206 MALAYSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 207 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 208 VIETNAM WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 VIETNAM MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 210 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 211 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 212 VIETNAM RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 213 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 214 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 215 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 SOUTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 217 SOUTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 219 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 220 SOUTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 221 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 BRAZIL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 BRAZIL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 225 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 226 BRAZIL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 227 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 ARGENTINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 ARGENTINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 231 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 232 ARGENTINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 233 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 234 PERU WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 235 PERU MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 236 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 237 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 238 PERU RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 239 REST OF SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 240 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 241 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 242 MIDDLE EAST AND AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 243 MIDDLE EAST AND AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 245 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 246 MIDDLE EAST AND AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 247 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 SOUTH AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 SOUTH AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 250 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 251 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 252 SOUTH AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 253 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 SAUDI ARABIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 SAUDI ARABIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 257 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 258 SAUDI ARABIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 259 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 260 U.A.E. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 261 U.A.E. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 263 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 264 U.A.E. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 265 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 ISRAEL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 267 ISRAEL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 268 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 269 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 270 ISRAEL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 271 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 272 EGYPT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 EGYPT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 275 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 276 EGYPT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 277 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 KUWAIT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 KUWAIT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 281 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 282 KUWAIT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 283 REST OF SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
그림 목록
FIGURE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION
FIGURE 2 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: END USER COVERAGE GRID
FIGURE 10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST RATE IN GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 13 AN INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE GROWTH OF THE GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 WET AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN 2023 AND 2031
FIGURE 15 EUROPE IS THE FASTEST-GROWING MARKET IN GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET
FIGURE 17 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2023
FIGURE 18 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 19 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 20 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, LIFELINE CURVE
FIGURE 21 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2023
FIGURE 22 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 23 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, CAGR (2024-2031)
FIGURE 24 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, LIFELINE CURVE
FIGURE 25 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 26 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 27 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 28 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 29 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SNAPSHOT (2023)
FIGURE 30 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
FIGURE 31 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
FIGURE 32 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
FIGURE 33 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
